MyFinsight
Home
Blog
About
Net proceeds from
the issuance of...
$1,039K
(21.95%↑ Y/Y)
Net proceeds from
the loan
$691K
Net cash provided by
financing activities
$1,730K
(103.29%↑ Y/Y)
Net decrease in cash
and cash...
$124K
(153.06%↑ Y/Y)
Canceled cashflow
$1,606K
Stock-based compensation
and expenses, net
$747K
(65.27%↑ Y/Y)
Accounts payable
$363K
(611.76%↑ Y/Y)
Other items
$254K
(1158.33%↑ Y/Y)
Accrued and other
liabilities
$151K
(125.21%↑ Y/Y)
Depreciation and
amortization
$56K
(-60.28%↓ Y/Y)
Deposits and advances
-$23K
(87.43%↑ Y/Y)
Operating lease asset
-$9K
(71.88%↑ Y/Y)
Claims and advances
-$3K
Net cash used in
operating activities
-$1,350K
(4.05%↑ Y/Y)
Net cash (used in)
provided by investing...
-$254K
(-143.79%↓ Y/Y)
Effects of exchange rate
changes on cash and cash...
-$2K
(-108.00%↓ Y/Y)
Canceled cashflow
$1,606K
Net loss
-$2,936K
(-83.61%↓ Y/Y)
Acquisition and development
of intangible...
$249K
(118.42%↑ Y/Y)
Purchase of property,
plant, and equipment
$5K
(-37.50%↓ Y/Y)
Accounts receivable, net
$20K
(-62.26%↓ Y/Y)
Back
Back
Cash Flow
IGC Pharma, Inc. (IGC)
IGC Pharma, Inc. (IGC)
source: myfinsight.com